EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zevra Therapeutics's enterprise value is $196.23 Mil.
Zevra Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $28.01 Mil. Therefore, Zevra Therapeutics's EV-to-Revenue for today is 7.01.
The historical rank and industry rank for Zevra Therapeutics's EV-to-Revenue or its related term are showing as below:
ZVRA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.02 Med: 7.03 Max: 16.03
Current: 7.15
During the past 11 years, the highest EV-to-Revenue of Zevra Therapeutics was 16.03. The lowest was 2.02. And the median was 7.03.
ZVRA's EV-to-Revenue is ranked better than 54.87% of 1037
companies
in the Biotechnology industry
Industry Median: 7.95
vs ZVRA: 7.15
The historical data trend for Zevra Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zevra Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Zevra Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's EV-to-Revenue falls into.
Zevra Therapeutics's current Enterprise Value is $196.23 Mil.
Zevra Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics's share price for today is $4.80.
Zevra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Zevra Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Zevra Therapeutics (Zevra Therapeutics) Business Description
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVRA has been successfully added to your 